Malaria in Early Life Study

NACompletedINTERVENTIONAL
Enrollment

757

Participants

Timeline

Start Date

July 21, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

May 17, 2017

Conditions
Plasmodium Falciparum MalariaPlasmodium Vivax Malaria
Interventions
DRUG

dihydroartemisinin-piperaquine

Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.

Trial Locations (1)

99971

Timika Research Facility, Timika

All Listed Sponsors
collaborator

Timika Research Facility, Indonesia

UNKNOWN

collaborator

Eijkman Institute for Molecular Biology

OTHER

collaborator

Menzies School of Health Research

OTHER

lead

Gadjah Mada University

OTHER

NCT02001428 - Malaria in Early Life Study | Biotech Hunter | Biotech Hunter